The $10,075 parcel of shares increases Mills’ total holding in the company to over 7.57 million shares.
READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised
The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January this year.
CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.
CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.